AMGEN INC

NASDAQ: AMGN (Amgen Inc.)

Kemas kini terakhir: 5 hari lalu, 12:31PM

337.81

0.32 (0.09%)

  • 1H 0.09%
  • 5H -2.21%
  • 1B 5.50%
  • 6B 16.49%
  • Tahun Ke Tarikh 30.29%
  • 1T 21.68%
  • 5T 49.18%
Penutupan Terdahulu 337.49
Buka 338.08
Jumlah Dagangan 1,208,841
Purata Dagangan (3B) 2,609,569
Modal Pasaran 181,904,146,432
Harga / Pendapatan (P/E TTM) 26.13
Harga / Pendapatan (P/E Ke hadapan) 15.70
Harga / Jualan (P/S) 5.20
Harga / Buku (P/B) 19.34
Julat 52 Minggu
253.30 (-25%) — 345.84 (2%)
Tarikh Pendapatan 3 Feb 2026
Hasil Dividen (DY TTM) 2.82%
Margin Keuntungan 17.39%
Margin Operasi (TTM) 28.73%
EPS Cair (TTM) 10.97
Pertumbuhan Hasil Suku Tahunan (YOY) 9.40%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -18.30%
Jumlah Hutang/Ekuiti (D/E MRQ) 924.46%
Nisbah Semasa (MRQ) 1.17
Aliran Tunai Operasi (OCF TTM) 12.19 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 13.09 B
Pulangan Atas Aset (ROA TTM) 7.04%
Pulangan Atas Ekuiti (ROE TTM) 105.67%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Menurun
Drug Manufacturers - General (Global) Menaik Menurun
Stok Amgen Inc. Menaik Menurun

AISkor Stockmoo

-0.8
Konsensus Penganalisis -1.5
Aktiviti Orang Dalam NA
Volatiliti Harga -3.0
Purata Bergerak Teknikal -2.5
Osilator Teknikal 4.0
Purata -0.75

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
AMGN 182 B 2.82% 26.13 19.34
GILD 154 B 2.55% 19.24 7.32
AZN 282 B 1.72% 30.18 6.26
SNY 121 B 4.45% 16.36 1.41
GRFS 7 B 1.96% 14.05 0.960
BIIB 27 B - 16.61 1.42

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Value
% Dimiliki oleh Orang Dalam 0.21%
% Dimiliki oleh Institusi 83.77%
Julat 52 Minggu
253.30 (-25%) — 345.84 (2%)
Julat Harga Sasaran
272.00 (-19%) — 381.00 (12%)
Tinggi 381.00 (Piper Sandler, 12.79%) Beli
Median 318.00 (-5.86%)
Rendah 272.00 (B of A Securities, -19.48%) Jual
Purata 326.71 (-3.29%)
Jumlah 3 Beli, 3 Pegang, 1 Jual
Harga Purata @ Panggilan 320.68
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
BMO Capital 03 Dec 2025 372.00 (10.12%) Beli 345.42
Truist Securities 24 Nov 2025 318.00 (-5.86%) Pegang 334.30
Piper Sandler 14 Nov 2025 381.00 (12.79%) Beli 336.74
Cantor Fitzgerald 06 Nov 2025 315.00 (-6.75%) Pegang 315.59
Morgan Stanley 05 Nov 2025 329.00 (-2.61%) Pegang 319.86
Wells Fargo 05 Nov 2025 300.00 (-11.19%) Beli 319.86
B of A Securities 26 Sep 2025 272.00 (-19.48%) Jual 272.98

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
24 Nov 2025 Pengumuman AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE
24 Nov 2025 Pengumuman AMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE
19 Nov 2025 Pengumuman FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
08 Nov 2025 Pengumuman AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
04 Nov 2025 Pengumuman AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
02 Nov 2025 CNBC Where the blockbuster weight loss drug market stands today — and what’s coming next
31 Oct 2025 Pengumuman AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND
31 Oct 2025 Pengumuman AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025
29 Oct 2025 Pengumuman AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS
17 Oct 2025 Pengumuman FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
06 Oct 2025 Pengumuman /C O R R E C T I O N -- Amgen/
02 Oct 2025 Pengumuman LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS
26 Sep 2025 Pengumuman AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS
09 Sep 2025 Pengumuman Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis
08 Sep 2025 Pengumuman AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Papar semua
Hasil Dividen (DY TTM) 2.82%
Purata Hasil Dividen 5T 3.06%
Nisbah Pembayaran 83.23%
Jangkaan Pembayaran Dividen Seterusnya Jun 2026
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
21 Nov 2025 31 Oct 2025 12 Dec 2025 2.38 Tunai
22 Aug 2025 01 Aug 2025 12 Sep 2025 2.38 Tunai
16 May 2025 04 Mar 2025 06 Jun 2025 2.38 Tunai
14 Feb 2025 10 Dec 2024 07 Mar 2025 2.38 Tunai
18 Nov 2024 25 Oct 2024 09 Dec 2024 2.25 Tunai
16 Aug 2024 02 Aug 2024 06 Sep 2024 2.25 Tunai
16 May 2024 06 Mar 2024 07 Jun 2024 2.25 Tunai
15 Feb 2024 12 Dec 2023 07 Mar 2024 2.25 Tunai
16 Nov 2023 24 Oct 2023 08 Dec 2023 2.13 Tunai
17 Aug 2023 01 Aug 2023 08 Sep 2023 2.13 Tunai
17 May 2023 07 Mar 2023 08 Jun 2023 2.13 Tunai
14 Feb 2023 12 Dec 2022 08 Mar 2023 2.13 Tunai
16 Nov 2022 28 Oct 2022 08 Dec 2022 1.94 Tunai
17 Aug 2022 03 Aug 2022 08 Sep 2022 1.94 Tunai
16 May 2022 02 Mar 2022 08 Jun 2022 1.94 Tunai
14 Feb 2022 03 Dec 2021 08 Mar 2022 1.94 Tunai
15 Nov 2021 21 Oct 2021 08 Dec 2021 1.76 Tunai
16 Aug 2021 30 Jul 2021 08 Sep 2021 1.76 Tunai
14 May 2021 03 Mar 2021 08 Jun 2021 1.76 Tunai
11 Feb 2021 16 Dec 2020 08 Mar 2021 1.76 Tunai
13 Nov 2020 21 Oct 2020 08 Dec 2020 1.6 Tunai
14 Aug 2020 23 Jul 2020 08 Sep 2020 1.6 Tunai
15 May 2020 04 Mar 2020 08 Jun 2020 1.6 Tunai
13 Feb 2020 11 Dec 2019 06 Mar 2020 1.6 Tunai
14 Nov 2019 22 Oct 2019 06 Dec 2019 1.45 Tunai
14 Aug 2019 02 Aug 2019 06 Sep 2019 1.45 Tunai
16 May 2019 07 Mar 2019 07 Jun 2019 1.45 Tunai
14 Feb 2019 07 Dec 2018 08 Mar 2019 1.45 Tunai
15 Nov 2018 23 Oct 2018 07 Dec 2018 1.32 Tunai
16 Aug 2018 31 Jul 2018 07 Sep 2018 1.32 Tunai
16 May 2018 07 Mar 2018 08 Jun 2018 1.32 Tunai
14 Feb 2018 12 Dec 2017 08 Mar 2018 1.32 Tunai
16 Nov 2017 24 Oct 2017 08 Dec 2017 1.15 Tunai
15 Aug 2017 28 Jul 2017 08 Sep 2017 1.15 Tunai
15 May 2017 07 Mar 2017 08 Jun 2017 1.15 Tunai
13 Feb 2017 20 Dec 2016 08 Mar 2017 1.15 Tunai
14 Nov 2016 14 Oct 2016 08 Dec 2016 1 Tunai
15 Aug 2016 22 Jul 2016 08 Sep 2016 1 Tunai
13 May 2016 02 Mar 2016 08 Jun 2016 1 Tunai
11 Feb 2016 15 Dec 2015 08 Mar 2016 1 Tunai
12 Nov 2015 14 Oct 2015 07 Dec 2015 0.79 Tunai
13 Aug 2015 28 Jul 2015 08 Sep 2015 0.79 Tunai
12 May 2015 04 Mar 2015 05 Jun 2015 0.79 Tunai
10 Feb 2015 17 Dec 2014 06 Mar 2015 0.79 Tunai
10 Nov 2014 17 Oct 2014 05 Dec 2014 0.61 Tunai
12 Aug 2014 25 Jul 2014 05 Sep 2014 0.61 Tunai
13 May 2014 05 Mar 2014 06 Jun 2014 0.61 Tunai
11 Feb 2014 13 Dec 2013 07 Mar 2014 0.61 Tunai
12 Nov 2013 16 Oct 2013 06 Dec 2013 0.47 Tunai
14 Aug 2013 26 Jul 2013 06 Sep 2013 0.47 Tunai
14 May 2013 06 Mar 2013 07 Jun 2013 0.47 Tunai
11 Feb 2013 13 Dec 2012 07 Mar 2013 0.47 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 9.52 4 2.82
2024 9.00 4 3.45
2023 8.52 4 2.96
2022 7.76 4 2.96
2021 7.04 4 3.13
2020 6.40 4 2.78
2019 5.80 4 2.41
2018 5.28 4 2.71
2017 4.60 4 2.65
2016 4.00 4 2.74
2015 3.16 4 1.95
2014 2.44 4 1.53
2013 1.88 4 1.65
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda